Recombinant human epidermal growth factor on oral mucositis induced by intensive chemotherapy with stem cell transplantation

American Journal of Hematology

Volumn 88, Issue 2, 2013, Pages 107-112

  Kim, Kyung Im ^a   Kim, Ji Won ^a,b   Lee, Hyun Jung ^b   Kim, Byung Su ^b   Bang, Soo Mee ^b   Kim, Inho ^a,b,c   Oh, Jung Mi ^a   Yoon, Sung Soo ^a,b,c   Lee, Jong Seok ^b   Park, Seonyang ^a,b,c   Kim, Byoung Kook ^a,b,c  

^a Seoul National University   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

MELPHALAN; OPIATE; PLACEBO; RECOMBINANT EPIDERMAL GROWTH FACTOR;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; DRINKING; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MOUTH PAIN; MUCOSA INFLAMMATION; NAUSEA; PARENTERAL NUTRITION; PRIORITY JOURNAL; QUALITY OF LIFE; SELF REPORT; STEM CELL TRANSPLANTATION; SWALLOWING; TASTE DISORDER;

ADOLESCENT; ADULT; ANALGESICS, OPIOID; DEGLUTITION DISORDERS; DOUBLE-BLIND METHOD; EPIDERMAL GROWTH FACTOR; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; ORAL SPRAYS; PARENTERAL NUTRITION; QUALITY OF LIFE; RECOMBINANT PROTEINS; SEVERITY OF ILLNESS INDEX; STOMATITIS; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

EID: 84872939833     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23359     Document Type: Article

References (27)

1. McGuire DB, Altomonte V, Peterson DE, et al. Patterns of mucositis and pain in patients receiving preparative chemotherapy and bone marrow transplantation. Oncol Nurs Forum 1993;20:1493-1502.
2. Woo SB, Sonis ST, Monopoli MM, et al. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer 1993;72:1612-1617.
3. Elting LS, Cooksley C, Chambers M, et al. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 2003;98:1531-1539.
4. Sonis ST, Oster G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001;19:2201-2205.
5. Langner S, Staber P, Schub N, et al. Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients. Bone Marrow Transplant 2008;42:275-279.
6. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004;351:2590-2598.
7. Bensinger W, Schubert M, Ang KK, et al. NCCN Task Force Report. prevention and management of mucositis in cancer care. J Natl Compr Canc Netw 2008;6 Suppl 1:S1-S21; quiz S22-24.
8. Cohen S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem 1962;237: 1555-1562.
9. Brown GL, Curtsinger L, 3rd, Brightwell JR, et al. Enhancement of epidermal regeneration by biosynthetic epidermal growth factor. J Exp Med 1986;163: 1319-1324.
10. Noguchi S, Ohba Y, Oka T. Effect of salivary epidermal growth factor on wound healing of tongue in mice. Am J Physiol 1991;260:E620-E625.
11. Lee KK, Jo HJ, Hong JP, et al. Recombinant human epidermal growth factor accelerates recovery of mouse small intestinal mucosa after radiation damage. Int J Radiat Oncol Biol Phys 2008;71:1230-1235.
12. Wu HG, Song SY, Kim YS, et al. Therapeutic effect of recombinant human epidermal growth factor (RhEGF) on mucositis in patients undergoing radiotherapy, with or without chemotherapy, for head and neck cancer: A double-blind placebo-controlled prospective phase 2 multi-institutional clinical trial. Cancer 2009;115:3699-3708.
13. Stiff PJ, Emmanouilides C, Bensinger WI, et al. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol 2006;24:5186-5193.
14. Stiff PJ, Erder H, Bensinger WI, et al. Reliability and validity of a patient self-administered daily questionnaire to assess impact of oral mucositis (OM) on pain and daily functioning in patients undergoing autologous hematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant 2006;37:393-401.
15. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 4.0, DCTD, NCI, NIH, DHHS. Available from: http://ctep.cancer.gov. Accessed June 1, 2012.
16. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-214.
17. Casagrande JT, Pike MC. An improved approximate formula for calculating sample sizes for comparing two binomial distributions. Biometrics 1978;34: 483-486.
18. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659-663.
19. Rosen LS, Abdi E, Davis ID, et al. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol 2006;24:5194-5200.
20. Elting LS, Shih YC, Stiff PJ, et al. Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results. Biol Blood Marrow Transplant 2007;13:806-813.
21. Sonis ST, Costa JW, Jr., Evitts SM, et al. Effect of epidermal growth factor on ulcerative mucositis in hamsters that receive cancer chemotherapy. Oral Surg Oral Med Oral Pathol 1992;74:749-755.
22. Soto E, Fall-Dickson JM, et al. Oral complications. In: DeVita VT, Lawrence TS, Rosenberg SA, editors. DeVita, Hellman & Rosenberg's Cancer: Principles & Practice of Oncology, 9th ed. Philadelphia, PA:Lippincott Williams & Wilkins;2011. p2338
23. Harris AL, Potter C, Bunch C, et al. Pharmacokinetics of cytosine arabinoside in patients with acute myeloid leukaemia. Br J Clin Pharmacol 1979;8:219-227.
24. Hersh MR, Ludden TM, Kuhn JG, Knight WA, 3rd. Pharmacokinetics of high dose melphalan. Invest New Drugs 1983;1:331-334.
25. Pfluger KH, Hahn M, Holz JB, et al. Pharmacokinetics of etoposide: correlation of pharmacokinetic parameters with clinical conditions. Cancer Chemother Pharmacol 1993;31:350-356.
26. Richard B, Launay-Iliadis MC, Iliadis A, et al. Pharmacokinetics of mitoxantrone in cancer patients treated by high-dose chemotherapy and autologous bone marrow transplantation. Br J Cancer 1992;65:399-404.
27. Arcangelo VP, Peterson AM. Pharmacotherapeutics for Advanced Practice: A Practical Approach, 2nd edn. Philadelphia:Lippincott Williams & Wilkins Press;2006.